Caldan Therapeutics Ltd, a Glasgow, UK-based diabetes startup, raised £4.45m in Series A funding.
The round was led by Epidarex Capital, an international early-stage life science venture capital fund, with participation from Scottish Enterprise’s investment arm, the Scottish Investment Bank.
A spin-out company from the Universities of Glasgow and Southern Denmark, Caldan develops novel therapeutics targeting free fatty acid receptors for Type 2 Diabetes (T2D) and other potential indications.
The company, which has arisen from a long-term collaboration between Professor Trond Ulven at the University of Southern Denmark and Professor Graeme Milligan of the University of Glasgow, aims to address the market need for T2D treatments that address all aspects of the disease, including insulin resistance, pancreatic islet cell failure, inappropriate insulin secretion, and inflammation in muscle, liver and adipose tissue.
Due to their involvement in multiple aspects of the disease process, free fatty acid receptors have emerged as exciting targets for T2D. Caldan is focused on creating drugs that activate these receptors in order to deliver a range of anti-diabetic effects in multiple tissues and organs which would provide a step change in the treatment of T2D.
FinSMEs
06/11/2015